Notice of Intent to Publish a Funding Opportunity Announcement for Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)

Active
No
Status
Forecasted
Estimated Post Date
January 26th, 2024
Estimated Close Date
June 14th, 2024
Estimated Award Date
July 1st, 2025
Total Funding
$1,000,000.00
Award Ceiling
$1,000,000.00
Expected No. Awards
1
Opportunity No.
NOT-DK-24-005

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed). This initiative aims to support the TrialNet Clinical Network Hub (HUB), which serves as a coordination unit for clinical trials focused on preventing and intervening early in type 1 diabetes (T1D). The HUB's main objective is to enhance the efficiency and productivity of the TrialNet network by coordinating communications and outreach, developing new tools and approaches for screening, recruitment, and retention. The funding opportunity will require applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) as part of the scientific and technical peer review evaluation. Failure to include a PEDP will result in the application being considered incomplete and withdrawn. The funding opportunity is expected to be published in Spring 2024, with an application due date in Summer 2024. The funding instrument type for this opportunity is a Cooperative Agreement, and the estimated total program funding is $1,000,000.

Description

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Clinical Network Hub (HUB). The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.� The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the TrialNet Coordinating Center (TNCC), which is part of the TrialNet network. The TNCC plays a crucial role in identifying individuals with type 1 diabetes (T1D) at different stages of the disease and enrolling them in trials and studies aimed at preventing the progression of clinical symptoms and preserving insulin production. The TNCC supports various research projects, manages data and samples, and oversees network administration and operations. The TNCC will also be responsible for evaluating, selecting, and funding Clinical Centers and central support units necessary for TrialNet's clinical studies. The TNCC PD/PI will be a voting member of the TrialNet Executive and Steering Committees. The funding opportunity announcement is expected to be published in Spring 2024, with an application due date in Summer 2024. The TNCC will be funded through a cooperative agreement, and the estimated total program funding is $29,500,000.
Notice of Intent to Publish a Notice of Funding Opportunity for Diabetes Research Centers (P30 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional). This initiative aims to solicit applications for research on diabetes, its complications, and related endocrine and metabolic diseases. The NOFO is expected to be published in Spring 2024, with an application due date in Summer 2024. The estimated total program funding is $7,500,000. The NOFO will utilize the P30 activity code. This opportunity falls under the category of Health and is a discretionary grant. The eligible applicants are others, and there is no cost sharing or matching requirement. The estimated synopsis post date is March 1, 2024, and the estimated synopsis close date is June 18, 2024. The estimated award date and project start date are both April 1, 2025.
Notice of Intent to Publish a Funding Opportunity Announcement for Justice Community Overdose Innovation Network - Phase II Research Hubs (U01 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the Justice Community Overdose Innovation Network - Phase II Research Hubs (U01 Clinical Trial Required). This initiative aims to promote research hubs to participate in Phase II of the Justice Community Overdose Innovation Network (JCOIN). The funding opportunity is expected to be published in Fall 2025, with an application due date in Winter 2025. The NIH intends to provide sufficient time for potential applicants to develop collaborations and responsive projects. The estimated total program funding is $20,000,000, with an award ceiling of $1,500,000. It is anticipated that there will be 11 awards granted. The funding instrument type is a Cooperative Agreement. The eligible applicants are Others. The category of funding activity is Health. The estimated synopsis post date is August 21, 2023, and the estimated synopsis close date is February 12, 2025. The estimated award date is August 1, 2025, and the estimated project start date is September 1, 2025.
Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed)". This grant aims to support research on human pancreatic tissues and the immune compartment to explore specific signaling or processing pathways related to the asymptomatic phase of Type 1 Diabetes (T1D). The goal is to discover early biomarkers of T1D pathogenesis, develop diagnostic tools for early detection and staging of T1D, and identify therapeutic targets for preventative or early treatment strategies. The grant will be awarded as a Cooperative Agreement and falls under the category of Health. The funding opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and Historically Black Colleges and Universities (HBCUs), among others. The deadline for applications is July 9, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-007.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-23-007.html).